1-[[2,3,4,6-Tetrachloro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-[[2,3,4,6-Tetrachloro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane
• 化学式: C₂₈H₅₀Cl₄N₈
• 分子量: 640.6
• InChiKey: PTDLVNBLFNWNGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  40
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  78.7
• 氢给体数：
  6
• 氢受体数：
  8

文献信息

• LINKED CYCLIC POLYAMINES WITH ACTIVITY AGAINST HIV
  申请人：AnorMED Inc.

  公开号：EP0619813B1

  公开（公告）日：2004-08-18
• Combination Therapy
  申请人：Bridger Gary J.

  公开号：US20100003224A1

  公开（公告）日：2010-01-07

  Methods to mobilize progenitor and/or stem cells from the bone marrow to the bloodstream by administering a combination of at least one CXCR4 inhibitor and at least one VLA-4 inhibitor are described. The combinations may also be used to treat multiple myeloma.
• CXCR4 ANTAGONISTS FOR KIDNEY INJURY
  申请人：Zuk Anna

  公开号：US20110245265A1

  公开（公告）日：2011-10-06

  Methods to treat or prevent acute kidney injury and chronic kidney injury in subjects using CXCR4 antagonists are disclosed.
• Use of CXCR4 Antagonists
  申请人：Dale David C.

  公开号：US20150030561A1

  公开（公告）日：2015-01-29

  Presently disclosed are methods and compositions for treating or preventing WHIM syndrome and certain other disorders or conditions with a certain CXCR4 antagonist.
• US7935692B2
  申请人：——

  公开号：US7935692B2

  公开（公告）日：2011-05-03